Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

J. Czech, S. Cordua, B. Weinbergerova, J. Baumeister, A. Crepcia, L. Han, T. Maié, IG. Costa, B. Denecke, A. Maurer, C. Schubert, K. Feldberg, D. Gezer, TH. Brümmendorf, G. Müller-Newen, J. Mayer, Z. Racil, B. Kubesova, T. Knudsen, AL. Sørensen,...

. 2019 ; 33 (4) : 995-1010. [pub] 20181123

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19034888
E-resources Online Full text

NLK ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Nursing & Allied Health Database (ProQuest) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Public Health Database (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 30470838
DOI 10.1038/s41375-018-0295-6
Knihovny.cz E-resources

Pegylated interferon-α (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30-40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F- vs. calreticulin (CALR)-mutated cells and investigated the mechanisms of differential response. Retrospective analysis of MPN patients treated with peg-IFNa demonstrated that patients harboring the JAK2V617F mutation were more likely to achieve PMR than those with mutated CALR (p = 0.004), while there was no significant difference in hematological response. In vitro experiments confirmed an upregulation of IFN-stimulated genes in JAK2V617F-positive 32D cells as well as patient samples (peripheral blood mononuclear cells and CD34+ hematopoietic stem cells) compared to their CALR-mutated counterparts, and higher IFNa doses were needed to achieve the same IFNa response in CALR- as in JAK2V617F-mutant 32D cells. Additionally, Janus-activated kinase-1 (JAK1) and signal transducers and activators of transcription 1 (STAT1) showed constitutive phosphorylation in JAK2V617F-mutated but not CALR-mutated cells, indicating priming towards an IFNa response. Moreover, IFN-induced growth arrest was counteracted by selective JAK1 inhibition but enhanced by JAK2 inhibition. In conclusion, our data suggest that, clinically, higher doses of IFNa are needed in CALR-mutated vs. JAK2V617F-positive patients and we suggest a model of JAK2V617F-JAK1/STAT1 crosstalk leading to a priming of JAK2V617F-positive cells to IFNa resulting in differential sensitivity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034888
003      
CZ-PrNML
005      
20191015103928.0
007      
ta
008      
191007s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-018-0295-6 $2 doi
035    __
$a (PubMed)30470838
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Czech, Julia $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
245    10
$a JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation / $c J. Czech, S. Cordua, B. Weinbergerova, J. Baumeister, A. Crepcia, L. Han, T. Maié, IG. Costa, B. Denecke, A. Maurer, C. Schubert, K. Feldberg, D. Gezer, TH. Brümmendorf, G. Müller-Newen, J. Mayer, Z. Racil, B. Kubesova, T. Knudsen, AL. Sørensen, M. Holmström, L. Kjær, V. Skov, TS. Larsen, HC. Hasselbalch, N. Chatain, S. Koschmieder,
520    9_
$a Pegylated interferon-α (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30-40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F- vs. calreticulin (CALR)-mutated cells and investigated the mechanisms of differential response. Retrospective analysis of MPN patients treated with peg-IFNa demonstrated that patients harboring the JAK2V617F mutation were more likely to achieve PMR than those with mutated CALR (p = 0.004), while there was no significant difference in hematological response. In vitro experiments confirmed an upregulation of IFN-stimulated genes in JAK2V617F-positive 32D cells as well as patient samples (peripheral blood mononuclear cells and CD34+ hematopoietic stem cells) compared to their CALR-mutated counterparts, and higher IFNa doses were needed to achieve the same IFNa response in CALR- as in JAK2V617F-mutant 32D cells. Additionally, Janus-activated kinase-1 (JAK1) and signal transducers and activators of transcription 1 (STAT1) showed constitutive phosphorylation in JAK2V617F-mutated but not CALR-mutated cells, indicating priming towards an IFNa response. Moreover, IFN-induced growth arrest was counteracted by selective JAK1 inhibition but enhanced by JAK2 inhibition. In conclusion, our data suggest that, clinically, higher doses of IFNa are needed in CALR-mutated vs. JAK2V617F-positive patients and we suggest a model of JAK2V617F-JAK1/STAT1 crosstalk leading to a priming of JAK2V617F-positive cells to IFNa resulting in differential sensitivity.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a antivirové látky $x farmakologie $7 D000998
650    _2
$a apoptóza $7 D017209
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a kalretikulin $x genetika $7 D037282
650    _2
$a proliferace buněk $7 D049109
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a interferon alfa $x farmakologie $7 D016898
650    _2
$a Janus kinasa 1 $x genetika $x metabolismus $7 D053613
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a myeloproliferativní poruchy $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D009196
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a transkripční faktor STAT1 $x genetika $x metabolismus $7 D050794
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cordua, Sabrina $u Department of Hematology, Zealand University Hospital, Copenhagen University Hospital, Roskilde, Denmark.
700    1_
$a Weinbergerova, Barbora $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Baumeister, Julian $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Crepcia, Assja $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Han, Lijuan $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Maié, Tiago $u Institute for Computational Genomics, Joint Research Center for Computational Biomedicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Costa, Ivan G $u Institute for Computational Genomics, Joint Research Center for Computational Biomedicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Denecke, Bernd $u Interdisciplinary Center for Clinical Research Aachen Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Maurer, Angela $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. Institute of Pathology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Schubert, Claudia $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Feldberg, Kristina $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Gezer, Deniz $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Brümmendorf, Tim H $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Müller-Newen, Gerhard $u Institute of Biochemistry and Molecular Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Racil, Zdenek $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Kubesova, Blanka $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Knudsen, Trine $u Department of Hematology, Zealand University Hospital, Copenhagen University Hospital, Roskilde, Denmark.
700    1_
$a Sørensen, Anders L $u Department of Hematology, Zealand University Hospital, Copenhagen University Hospital, Roskilde, Denmark.
700    1_
$a Holmström, Morten $u Department of Hematology, Zealand University Hospital, Copenhagen University Hospital, Roskilde, Denmark.
700    1_
$a Kjær, Lasse $u Department of Hematology, Zealand University Hospital, Copenhagen University Hospital, Roskilde, Denmark.
700    1_
$a Skov, Vibe $u Department of Hematology, Zealand University Hospital, Copenhagen University Hospital, Roskilde, Denmark.
700    1_
$a Larsen, Thomas Stauffer $u Department of Hematology, Odense University Hospital, Odense, Denmark.
700    1_
$a Hasselbalch, Hans C $u Department of Hematology, Zealand University Hospital, Copenhagen University Hospital, Roskilde, Denmark.
700    1_
$a Chatain, Nicolas $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
700    1_
$a Koschmieder, Steffen $u Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. skoschmieder@ukaachen.de.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 33, č. 4 (2019), s. 995-1010
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30470838 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015104354 $b ABA008
999    __
$a ok $b bmc $g 1451548 $s 1073438
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 33 $c 4 $d 995-1010 $e 20181123 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options